Table 1 FDA-approved monoclonal antibodies to treat colorectal cancer

Nivolumab

PD-1

microsatellite instability-high (MSI-H) subgroups of patients with advanced colorectal cancer

Pembrolizumab

PD-1

for subgroups of patients with advanced colorectal cancer who have substantial tumor mutational burden, DNA mismatch repair deficiency (dMMR), or microsatellite instability (MSI-H)

Dostarlimab

PD-1

for specific groups of patients with advanced colorectal cancer who suffer from a DNA mismatch repair (dMMR) deficit

Ipilimumab

CTLA-4

for certain subsets of patients with advanced, high-microsatellite-instability colorectal cancer (MSI-H) (in conjunction with nivolumab)

Bevacizumab

VEGF-A

for subsets of patients with advanced colorectal cancer

Ramucirumab

VEGFR2

for subsets of patients with advanced colorectal cancer

Cetuximab

EGFR

for subsets of patients with advanced, EGFR-positive colorectal cancer

Panitumumab

EGFR

for subsets of patients with advanced, EGFR-positive colorectal cancer